Option chain shows key data for PAO Group's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for PAO Group.

PAO Group (OTC:PAOG) Stock, Option Chain

PAO Group Inc is a United States-based holding company. It seeks to develop, acquire, partner, or participate in, companies and concepts in the development and launch of alternative medicine clinics focused on non-traditional patient care solutions. The range of treatment solutions includes cannabis, acupuncture, chiropractic, biofeedback, and other solutions depending on patient needs. The group operates in the United States of America.

Cannabis

News

Markets

PAOG

PURA

USMJ

Puration, Inc. (OTCPK:PURA) and PAO Group, Inc. (OTCPK:PAOG) are working together on a new line of CBD Nutraceuticals under PURA’s Farmersville Hemp Brand Name for the women’s health market.

PURA And PAOG To Launch CBD Product Line For Women&#39;s Health Market In April

Penny Stocks

Real Estate

ALKM

UCASU

UC Asset LP (OTC: UCASU) and Puration, Inc.

UC Asset LP To Provide Cannabis Real Estate Financing Via PURA Farmersville Hemp Brand COOP

PAO Group, Inc. (Pink: PAOG), a holding company focused on alternative patient treatments, confirmed Friday it will launch a CBD Nutraceuticals line of products.

PAO Group Teams Up With Puration, Alkame, North American Cannabis Holdings On New CBD Nutraceuticals

PAO Group Inc

Buybacks

ADT Announces New $500M Share Buyback Program

WIIM

LFST

LifeStance Health shares are trading higher after the company reported better-than-expected Q4 results and issued FY25 revenue guidance above estimates.

Needham analyst Mayank Tandon maintains ExlService Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXLS#NASDAQ">EXLS</a>) with a Buy and raises the price target from $50 to $60.

Price Target

Analyst Ratings

EXLS

Needham Maintains Buy on ExlService Hldgs, Raises Price Target to $60

ADT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADT#NYSE">ADT</a>) reported quarterly earnings of $0.20 per share which beat the analyst consensus estimate of $0.19 by 5.26 percent. This is a 20 percent decrease over earnings of $0.25 per share from the same period last year. The company reported quarterly sales of $1.30 billion which beat the analyst consensus estimate of $1.23 billion by 5.41 percent. This is a 6.38 percent increase over sales of $1.22 billion the same period last year.

Earnings

Earnings Beats

ADT Q4 2024 Adj EPS $0.20 Beats $0.19 Estimate, Sales $1.30B Beat $1.23B Estimate

XRAY

Dentsply Sirona shares are trading lower after the company reported worse-than-expected Q4 FY24 financial results and issued guidance.

Guidance

GLNG

Golar LNG Reports Preliminary Q4 Net Income Attributable Of $3M Inclusive Of $29M Of Non-cash Items, And Adjusted EBITDA Of $59M

Barclays analyst Peter Lawson maintains Geron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GERN#NASDAQ">GERN</a>) with a Overweight and lowers the price target from $9 to $4.

GERN

Barclays Maintains Overweight on Geron, Lowers Price Target to $4

NCLH

Norwegian Cruise Line shares are trading higher after the company reported better-than-expected Q4 EPS and revenue.

Teleflex shares are trading lower after the company issued FY25 EPS guidance below estimates.

WRBY

Warby Parker shares are trading higher after the company reported Q4 sales above estimates.

Barclays analyst Jeffrey Bernstein maintains Bloomin Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLMN#NASDAQ">BLMN</a>) with a Equal-Weight and lowers the price target from $13 to $11.

BLMN

Barclays Maintains Equal-Weight on Bloomin Brands, Lowers Price Target to $11

2025 Full-Year Financial Guidance1
The Company's full-year guidance for 2025 can be found in the table below.
Updates to Subsea guidance, previously issued on October 24, 2024, are as follows:
<ul>
<li>Subsea revenue in a range of $8.4 - 8.8 billion, which increased from the previous guidance range of $8.3 - 8.7 billion.</li>
<li>Subsea adjusted EBITDA margin in a range of 19 - 20%, which increased from the previous guidance range of 18.5 - 20%.</li>
</ul>
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="5" rowspan="1">2025 Guidance (As of February 27, 2025)</td>
</tr>
<tr>
<td colspan="5" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="2" rowspan="1">Subsea</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="2" rowspan="1">Surface Technologies</td>
</tr>
<tr>
<td colspan="2" rowspan="1">Revenue in a range of $8.4 - 8.8 billion</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="2" rowspan="1">Revenue in a range of $1.2 - 1.35 billion</td>
</tr>
<tr>
<td colspan="2" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="2" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="2" rowspan="1">Adjusted EBITDA margin in a range of 19 - 20%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="2" rowspan="1">Adjusted EBITDA margin in a range of 15 - 16%</td>
</tr>
<tr>
<td colspan="5" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="5" rowspan="1">TechnipFMC</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="5" rowspan="1">Corporate expense, net $115 - 125 million</td>
</tr>
<tr>
<td colspan="5" rowspan="1">(excludes charges and credits)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="5" rowspan="1">Net interest expense $45 - 55 million</td>
</tr>
<tr>
<td colspan="5" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="5" rowspan="1">Effective tax rate 28 - 32%</td>
</tr>
<tr>
<td colspan="5" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="5" rowspan="1">Capital expenditures approximately $340 million</td>
</tr>
<tr>
<td colspan="5" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="5" rowspan="1">Free cash flow2 $850 million - 1 billion</td>
</tr>
</tbody>
</table>
</figure>

TechnipFMC 2025 Outlook: Raised Subsea Revenue Range To $8.4B - $8.8B From $8.3B - 8.7B And Adj. EBITDA Margin Range To 19% - 20% From 18.5% - 20%.

HC Wainwright &amp; Co. analyst Mitchell Kapoor reiterates Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) with a Sell and maintains $75 price target.

Reiteration

SRPT

HC Wainwright & Co. Reiterates Sell on Sarepta Therapeutics, Maintains $75 Price Target

VTRS

Viatris shares are trading lower after the company reported Q4 EPS and sales below estimates.

2025 Financial Guidance
The Company is providing the following financial guidance metrics for fiscal year 2025.
The Company's financial guidance metrics for fiscal year 2025 include the anticipated negative impact from the Indore facility of ~$500 million to total revenues and ~$385 million to adjusted EBITDA. The Company is not providing forward-looking guidance for U.S. GAAP net earnings (loss) or U.S. GAAP diluted earnings (loss)&nbsp;per share (EPS) or a quantitative reconciliation of its 2025 adjusted EBITDA or adjusted EPS guidance to the most directly comparable U.S. GAAP measures, U.S. GAAP net earnings (loss) or U.S. GAAP diluted EPS, respectively, because it is unable to predict with reasonable certainty the ultimate outcome of certain significant items, including integration, acquisition and divestiture-related expenses, restructuring expenses, asset impairments, litigation settlements, and other contingencies, such as changes to contingent consideration, acquired IPR&amp;D and certain other gains or losses, including for the fair value accounting for non-marketable equity investments, as well as related income tax accounting, because certain of these items have not occurred, are out of the Company's control and/or cannot be reasonably predicted without unreasonable effort. These items are uncertain, depend on various factors, and could have a material impact on U.S. GAAP reported results for the guidance period. U.S. GAAP net cash provided by operating activities for 2025 is estimated to be between $2.2 billion and $2.5 billion, with a midpoint of approximately $2.35 billion.
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">(In millions, except Adjusted EPS)</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Estimated Guidance&nbsp; Range</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Midpoint</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Total Revenues</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$13,500 - $14,000</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$13,750</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA (1)(2)</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$3,900 - $4,200</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$4,050</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EPS (1)(2)</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$2.12 - $2.26</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$2.19</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Free Cash Flow (1)(2)</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$1,800 - $2,200</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$2,000</td>
</tr>
</tbody>
</table>
</figure>

Viatris FY2025 Outlook: Adj EPS $2.12-$2.26 vs $2.60 Estimate; Sees Sales $13.500B-$14.000B vs $14.31B Estimate

Offerings

SLB Subsidiary Commences Offer To Exchange Certain Outstanding Existing Series Of Notes For Up To $2B Of New Series Of Notes

Viatris (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTRS#NASDAQ">VTRS</a>) reported quarterly earnings of $0.54 per share which missed the analyst consensus estimate of $0.57 by 5.26 percent. This is a 12.9 percent decrease over earnings of $0.62 per share from the same period last year. The company reported quarterly sales of $3.52 billion which missed the analyst consensus estimate of $3.61 billion by 2.75 percent. This is a 8.13 percent decrease over sales of $3.83 billion the same period last year.

Earnings Misses

Viatris Q4 2024 Adj EPS $0.54 Misses $0.57 Estimate, Sales $3.52B Miss $3.61B Estimate

HC Wainwright &amp; Co. analyst Ed Arce maintains Madrigal Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDGL#NASDAQ">MDGL</a>) with a Buy and raises the price target from $400 to $405.

MDGL

HC Wainwright & Co. Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $405

Warby Parker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WRBY#NYSE">WRBY</a>) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of $(0.05) by 20 percent. The company reported quarterly sales of $190.64 million which beat the analyst consensus estimate of $187.64 million by 1.60 percent. This is a 17.79 percent increase over sales of $161.85 million the same period last year.

Warby Parker Q4 2024 GAAP EPS $(0.06) Misses $(0.05) Estimate

The planned spin-off will result in two separate, publicly traded companies:
<ul>
<li>Costamare Inc. will remain a global container shipping provider, retaining the owned container vessels and Neptune Maritime Leasing Limited businesses.</li>
<li>Costamare Bulkers Holdings Limited will be an international owner and operator of dry bulk vessels and will hold the owned dry bulk vessels and the CBI operating platform.</li>
</ul>

Comments

PAO Group

PAO Group (PAOG) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga